HF1652 Summary

• Adds tramadol, butalbital, and gabapentin to the list of controlled substances tracked by Minnesota's prescription monitoring program.

• Makes the Prescription Monitoring Program Advisory Task Force permanent instead of allowing it to expire, and adds representation from medical examiners and coroners.

• Restricts direct electronic access to prescription monitoring data to only prescribers, dispensers, licensed pharmacists, board personnel, contractors, law enforcement with warrants, and Minnesota health care programs.

• Requires all prescribers authorized to prescribe controlled substances and all pharmacists in Minnesota to register with the prescription monitoring program by July 1, 2017.

• Limits data retention to four years and requires data older than 24 months to be de-identified, while prohibiting licensing board access to data for initiating disciplinary actions without a search warrant or court order.